Sihuan Pharmaceutical Holdings Group (0460) AI Stock Analysis

• Market Cap: $9.61B
• Dividend Yield: 2.04%
• Average Volume (3M): 116.89M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: -0.11%
• EPS Growth: -290.77%
• Country: HK
• Employees: 2,667
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 9,329,999,000
• 10 Day Avg. Volume: 148,388,157
• 30 Day Avg. Volume: 116,892,988
• PEG Ratio: 0.06
• Price to Book (P/B): 1.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -506.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: ―

Sihuan Pharmaceutical's overall stock score reflects significant financial challenges, including declining revenues, net losses, and cash flow volatility. While technical indicators show short-term positive momentum, the valuation and financial health issues weigh heavily. The company must address these financial issues to improve its overall stock performance.

Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model

Company Description

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.

How the Company Makes Money

Sihuan Pharmaceutical Holdings Group generates revenue through the sale of its pharmaceutical products, which include both branded and generic drugs. Key revenue streams include hospital sales, distribution through pharmacies, and partnerships with other pharmaceutical companies for research and development. The company benefits from a strong presence in China’s healthcare sector, and it leverages strategic alliances and collaborations to expand its market reach and enhance its product offerings. Additionally, Sihuan invests in research and development to innovate and bring new drugs to market, thereby ensuring a steady flow of revenue from its diverse product portfolio.

Sihuan Pharmaceutical Holdings Group Financial Statement Overview

Summary

Sihuan Pharmaceutical is experiencing significant financial challenges. The income statement shows declining revenues and consistent net losses. The balance sheet is mixed, with a low debt-to-equity ratio but decreasing stockholders' equity. Cash flow volatility and negative free cash flow highlight liquidity issues. Overall, the company needs to address revenue declines, improve profitability, and stabilize cash flows.

Income Statement

Sihuan Pharmaceutical's income statement reflects significant challenges in recent years. The company experienced a substantial decline in revenue from 2021 to 2024, with revenue decreasing from approximately 3.04 billion to 1.90 billion. Gross profit margins have remained relatively stable, but consistent net losses have been reported, indicating profitability issues. The EBIT and EBITDA margins have turned negative, suggesting operational inefficiencies and a need for cost management improvements.

Balance Sheet

The balance sheet indicates a mixed financial position. The company's debt-to-equity ratio is low, which is positive, but stockholders' equity has decreased over time. The equity ratio remains adequate, reflecting a stable asset base. However, the decline in total assets and stockholders' equity raises concerns about long-term financial stability.

Cash Flow

Cash flow analysis shows significant volatility. The company's free cash flow has fluctuated, with recent years showing negative free cash flow, indicating potential liquidity issues. Operating cash flow has also been inconsistent, with the most recent period showing zero, highlighting challenges in generating cash from operations. These factors suggest a need for improved cash flow management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.90B	1.86B	2.18B	3.04B	2.46B
	Gross Profit
1.24B	1.30B	1.49B	2.43B	1.91B
	EBIT
-138.13M	161.70M	-536.03M	676.20M	485.82M
	EBITDA
-208.66M	334.31M	-1.54B	931.69M	714.06M
	Net Income Common Stockholders
-216.66M	-54.02M	-1.95B	416.51M	473.38M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.63B	4.37B	4.79B	5.79B	4.94B
	Total Assets
10.53B	11.54B	12.14B	14.50B	13.04B
	Total Debt
942.76M	1.26B	1.19B	1.08B	755.05M
	Net Debt
-2.58B	-2.63B	-2.63B	-4.60B	-3.85B
	Total Liabilities
5.58B	6.40B	6.50B	5.35B	3.10B
	Stockholders Equity
4.37B	4.43B	4.74B	8.28B	9.19B
Cash Flow		Free Cash Flow
0.00	-95.93M	-355.97M	64.28M	-279.51M
	Operating Cash Flow
0.00	199.49M	46.49M	665.29M	227.13M
	Investing Cash Flow
0.00	169.88M	-1.66B	-337.57M	-924.78M
	Financing Cash Flow
0.00	-419.56M	-238.93M	750.66M	184.54M

Sihuan Pharmaceutical Holdings Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0460, the sentiment is Positive. The current price of 1.03 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.73, and above the 200-day MA of 0.65, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 76.66 is Negative, neither overbought nor oversold. The STOCH value of 86.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0460.

Sihuan Pharmaceutical Holdings Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
0460	51 Neutral	$9.61B	―	-4.93%	2.04%	-0.11%	-290.77%
CHIZF		$1.41B	159.33	0.25%	―	―	―
C1P		€1.06B	7.72	23.28%	6.45%	―	―
0719	70 Outperform	HK$9.38B	8.79	8.89%	4.93%	4.91%	-11.80%
1558	66 Neutral	HK$11.49B	21.98	5.88%	―	-42.02%	-76.29%
6185	48 Neutral	HK$10.61B	―	-4.41%	―	94.98%	85.69%

Sihuan Pharmaceutical Holdings Group Corporate Events

Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Plan

Sihuan Pharmaceutical Holdings Group Ltd. has announced a share repurchase plan of up to HK$500 million, reflecting its confidence in the company’s future prospects and commitment to enhancing shareholder value. This move aligns with its strategic goals, as the company continues to expand its medical aesthetics and biopharmaceutical businesses, with significant growth reported in its medical aesthetics segment and several new product approvals expected to boost revenue.

Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Plan

Sihuan Pharmaceutical Holdings Group Ltd. announced a voluntary share repurchase plan, aiming to buy back shares worth up to HK$500 million, subject to market conditions. This move reflects the company’s confidence in its strategic direction and is expected to positively impact its financial performance. The company has made significant strides in its medical aesthetics and innovative pharmaceuticals segments, with a notable increase in revenue and several products reaching critical development milestones. These advancements are anticipated to enhance Sihuan’s market position and contribute to its future growth.

Sihuan Pharmaceutical Announces Share Repurchase Amidst Business Growth

Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase plan, buying back 16,174,000 shares at an average price of HK$0.6731 per share, totaling approximately HK$10.89 million. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in future growth. The company has seen significant progress in its medical aesthetics and innovative pharmaceuticals businesses, with a notable increase in revenue and the approval of new products. These developments are expected to positively impact the company’s revenue and profit, strengthening its position in the industry.

Sihuan Pharmaceutical Announces 2025 Annual General Meeting

Sihuan Pharmaceutical Holdings Group Ltd. has announced its annual general meeting scheduled for June 6, 2025, in Beijing, China. The meeting will cover the adoption of the company’s financial statements for 2024, re-election of directors, re-appointment of auditors, and resolutions regarding the issuance of additional shares. These resolutions, if passed, could influence the company’s financial strategies and shareholder value.

Sihuan Pharmaceutical’s Breakthrough in Regenerative Aesthetics with PLLA Filler Approval

Sihuan Pharmaceutical Holdings Group has achieved a significant milestone with its subsidiary, Meiyan Space, obtaining Class III medical device registration approval from China’s National Medical Products Administration for its Poly-L-lactic Acid Facial Filler (PLLA filler). This development strengthens Sihuan’s position in the regenerative medical aesthetic market, highlighting its technological leadership and competitive advantage. The approval is expected to drive the company’s growth in the medical aesthetic segment, supported by the rapidly expanding market for regenerative biomaterials in China.

Sihuan Pharmaceutical’s Dapagliflozin Tablets Gain Approval, Boosting Diabetes Treatment Portfolio

Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, received approval from China’s National Medical Products Administration for its Dapagliflozin Tablets, a treatment for type 2 diabetes. This approval enhances the company’s product lineup in the diabetes sector and provides improved treatment options for patients, aligning with the growing market demand for SGLT-2 inhibitors, which are recognized for their efficacy in managing blood glucose and offering cardiovascular and renal benefits.

Sihuan Pharmaceutical Announces Strategic Share Repurchase Plan

Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase plan of up to HK$500 million, with a recent repurchase of 10 million shares at an average price of HK$0.6274 per share. This move is part of the company’s strategic goal to strengthen its market position in medical aesthetics and biopharmaceuticals, with significant growth reported in its medical aesthetics segment and ongoing development of innovative drugs. The company expects these developments to positively impact its revenue and profit, reinforcing its confidence in future growth.

Sihuan Pharmaceutical’s Breakthrough in Breast Cancer Treatment

Sihuan Pharmaceutical Holdings Group Ltd. announced significant results from a phase 3 clinical trial of its innovative drug Bireociclib, in combination with Fulvestrant, for treating HR+/HER2- advanced breast cancer. The study, published in Nature Communications, demonstrated that the combination therapy significantly improved progression-free survival compared to Fulvestrant alone, marking a notable advancement in treatment options for complex and refractory breast cancer cases. This achievement underscores Sihuan Pharmaceutical’s strong R&D capabilities and commitment to addressing unmet clinical needs, enhancing its position in the pharmaceutical industry.

Sihuan Pharmaceutical Announces Share Repurchase Amidst Strong Business Growth

Sihuan Pharmaceutical Holdings Group Ltd. announced a share repurchase plan, buying back 10 million shares at an average price of HK$0.5866 per share, totaling approximately HK$5.87 million. This initiative is part of the company’s strategy to enhance shareholder value and reflects its confidence in future growth prospects. Sihuan Pharmaceutical has made significant strides in its medical aesthetics and innovative pharmaceuticals sectors, with substantial revenue growth and new product approvals, positioning itself as a leader in the Chinese market.

Sihuan Pharmaceutical Announces Share Repurchase Amidst Strong Business Growth

Sihuan Pharmaceutical Holdings Group Ltd. announced a voluntary share repurchase plan, buying back 15 million shares at an average price of HK$0.5836 per share, totaling approximately HK$8.75 million. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in its future growth, driven by significant advancements in its medical aesthetics and innovative pharmaceuticals segments. The company reported a 65.4% year-on-year increase in revenue from its medical aesthetics business, and it has received approval for 21 new drugs in 2024, which are expected to boost future revenue and profit.

Sihuan Pharmaceutical Gains Approval for Innovative Facial Filler

Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Meiyan Space Biological Technology, has received approval from China’s National Medical Products Administration for its Injectable Polycaprolactone Microsphere Facial Filler. This product, known as ‘PCL filler,’ marks a significant advancement in the medical aesthetics sector, offering long-lasting effects with a single treatment. The approval fills a gap in the company’s class III medical device offerings and aligns with its strategy to expand in the regenerative materials market. The market for such materials is rapidly growing, with the ‘PCL filler’ gaining popularity due to its effectiveness and consumer appeal, positioning Sihuan Pharmaceutical as a potential leader in this fast-growing sector.

Sihuan Pharmaceutical Expands Stake in Meifu Company with Capital Increase

Sihuan Pharmaceutical Holdings Group Ltd. announced a capital increase agreement involving its subsidiary, Meifu Company. The agreement will see Meifu Company’s registered capital rise from RMB1 million to RMB50 million, with Meiyan Space and Hainan Temmei contributing RMB25.5 million and RMB23.5 million, respectively. This move will result in Meiyan Space holding a 51% stake, making Meifu Company a subsidiary of Sihuan Pharmaceutical. The capital increase is aimed at leveraging Meifu Company’s resources and expertise in the medical aesthetics field, enhancing market presence, and mitigating competition risks.

Sihuan Pharmaceutical Reports 2024 Financial Results with Mixed Performance

Sihuan Pharmaceutical Holdings Group Ltd. announced its annual results for the year ended December 31, 2024, reporting a total revenue increase of 2.2% to RMB1,901.1 million. The company experienced significant growth in its medical aesthetics business, with a 65.4% rise in sales revenue, while its generic medicine business saw a decline due to centralized procurement and regulatory changes. The innovative medicine segment showed a substantial increase in revenue, attributed to the launch of Anaprazole Sodium. Despite these shifts, the company faced an operating loss of RMB138.1 million, primarily due to increased share-based payments.

Sihuan Pharmaceutical to Approve Annual Results and Dividend

Sihuan Pharmaceutical Holdings Group Ltd. has announced a board meeting scheduled for March 28, 2025, to approve the annual results for the year ended December 31, 2024, and discuss the potential payment of a final dividend. This meeting is significant as it will determine the company’s financial performance and shareholder returns, impacting its market positioning and stakeholder interests.

Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Amidst Business Growth

Sihuan Pharmaceutical Holdings Group has announced a share repurchase initiative, with plans to buy back shares worth up to HK$500 million, reflecting the company’s confidence in its strategic direction and growth prospects. The initiative follows recent business advancements, including significant growth in its medical aesthetics segment and progress in innovative drug development, which are expected to enhance the company’s revenue and market position.